Treatment of Hepatic Steatosis (Non-Alcoholic Fatty Liver Disease)
Lifestyle modification with weight loss of 7-10% is the cornerstone treatment for all NAFLD patients, while pharmacotherapy should be reserved exclusively for biopsy-proven NASH with significant fibrosis (≥F2) or high-risk features. 1, 2
Who Requires Treatment
All NAFLD Patients (Regardless of Disease Stage)
- Lifestyle modifications are mandatory for every NAFLD patient 1
- Treatment of metabolic comorbidities (diabetes, hypertension, dyslipidemia) is essential 1
- Patients with simple steatosis (NAFL) without inflammation or fibrosis should receive only lifestyle counseling—no pharmacotherapy for liver disease 2
Candidates for Pharmacologic Therapy
Pharmacotherapy should target patients with: 1, 2
- Biopsy-proven NASH with stage 2-3 fibrosis (F2-F3)
- NASH with bridging fibrosis or cirrhosis
- Early-stage NASH with high-risk features: age >50 years, diabetes, metabolic syndrome, or elevated ALT 2
Lifestyle Interventions (First-Line for All Patients)
Weight Loss Targets
Achieve progressive weight loss at a rate <1 kg/week to avoid worsening portal inflammation and fibrosis 1
Weight loss thresholds for histologic improvement: 1, 3, 1
- 5-7% weight loss: Reduces hepatic fat and inflammation
- 7-10% weight loss: Improves liver enzymes and histology, recommended target 2
- >10% weight loss: Improves fibrosis in 45% of patients 1
Critical caveat: Rapid weight loss (>1.6 kg/week) can worsen portal inflammation and fibrosis in morbidly obese patients and may precipitate acute hepatic failure after bariatric surgery 1
Dietary Recommendations
Adopt a Mediterranean diet pattern with caloric restriction 2, 4
- Energy restriction: 1,200-1,500 kcal/day for women; 1,500-1,800 kcal/day for men (500+ kcal/day deficit) 1
- Exclude processed foods and beverages high in added fructose 2, 4
- Increase fiber, antioxidant-rich fruits, and vegetables 5
- Mediterranean diet reduces liver fat more effectively than low-fat/high-carbohydrate diets 2
Alcohol consumption: Total abstinence is mandatory in NASH-cirrhosis to reduce HCC risk 2
Physical Activity
Prescribe 150-200 minutes/week of moderate-intensity aerobic exercise in 3-5 sessions (brisk walking, stationary cycling) 2
- Vigorous exercise (running) provides greater benefit than moderate exercise for NASH and fibrosis 2
- Resistance training is also effective and promotes musculoskeletal fitness with metabolic benefits 2
- Any increase in physical activity is better than continued inactivity 2
Pharmacologic Therapy (For NASH with Significant Fibrosis)
FDA-Approved Treatment (2025)
Semaglutide (Wegovy®) 2.4 mg/week subcutaneous injection received accelerated FDA approval in August 2025 for MASH with moderate to advanced fibrosis (F2-F3) 6
Efficacy at 72 weeks: 6
- MASH resolution without worsening fibrosis: 62.9% vs 34.3% placebo (p<0.001)
- ≥1 stage fibrosis reduction without worsening MASH: 36.8% vs 22.4% placebo (p<0.001)
Patient selection for semaglutide: 6
- MASH with stage 2-3 fibrosis identified by non-invasive tests:
- VCTE: 8-15 kPa
- MRE: 3.1-4.4 kPa
- ELF: 9.2-10.5
- Not approved for MASH cirrhosis (VCTE>20 kPa, MRE>5.0 kPa, ELF>11.3)
Monitoring: 6
- Most common adverse events: gastrointestinal (nausea, diarrhea, constipation, vomiting)—generally mild and transient
- Monitor for rare serious risks: acute kidney injury from dehydration, symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, lean mass loss
- No routine hepatic panels required unless clinically indicated
Off-Label Pharmacotherapy (Pre-Semaglutide Era)
- Improves NASH in non-diabetic patients with biopsy-proven disease
- Safety concerns for long-term use must be considered 1
- Not recommended for diabetic patients
- Improves all histological features except fibrosis in NASH patients
- Can be used in select patients with biopsy-proven NASH
- Consider side effects: weight gain, bone loss, heart failure risk
Metformin: Scarce evidence for histological efficacy; not recommended specifically for NASH treatment 2, 3, 7
Management of Metabolic Comorbidities
Dyslipidemia
Statins should be used to treat dyslipidemia in NAFLD/NASH patients 8, 1, 9
- Statins are safe in NAFLD and compensated cirrhosis; hepatotoxicity is very rare 1, 9
- Do not withhold statins due to NAFLD diagnosis 8, 9
- Statins should not be used specifically to treat NASH (no histological efficacy proven) 8
- Omega-3 fatty acids: not recommended for NASH treatment but may be used for hypertriglyceridemia 1
Type 2 Diabetes
GLP-1 receptor agonists are preferred for patients with both NAFLD and diabetes 9, 10
- Provide cardiovascular benefit and weight loss
- Pioglitazone can be considered for diabetic patients with NASH 10
Hypertension
Manage according to standard guidelines with pharmacological therapy to optimize blood pressure and reduce cardiovascular risk 9
Monitoring and Follow-Up
Non-Invasive Test Monitoring
Treatment response indicators at 72 weeks: 6
- ALT reduction >17 U/L or ≥20%
- CAP reduction ≥30%
- VCTE LSM reduction ≥30%
- MRE LSM reduction ≥20%
- ELF reduction ≥0.5
Non-response suspected if: ALT or non-invasive tests worsen from baseline 6
Surveillance Requirements
- HCC surveillance: Required for patients with NASH cirrhosis 1, 8
- Variceal screening: According to standard guidelines for NASH cirrhosis 8
- Cardiovascular risk assessment: NAFLD patients have increased CVD mortality; aggressive risk factor modification is essential 1, 9
Key Clinical Pitfalls to Avoid
- Do not prescribe pharmacotherapy for simple steatosis without NASH or fibrosis 2
- Avoid rapid weight loss (>1.6 kg/week) in obese patients—can worsen liver disease 1
- Do not withhold statins from NAFLD patients due to unfounded hepatotoxicity concerns 8, 1, 9
- Do not use metformin specifically to treat NASH—insufficient histological efficacy 2, 3
- Ensure total alcohol abstinence in NASH-cirrhosis to reduce HCC risk 2